Executives at RA Capital, including Managing Partner Peter Kolchinsky, have made significant purchases of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) stock, totaling approximately $13.3 million. The transactions, which took place over a series of days, saw the acquisition of shares at prices ranging from $9.06 to $9.79.
Between March 25th and March 27th, the executives engaged in multiple transactions to buy shares of ARS Pharmaceuticals. On the first day, 437,600 shares were acquired at a weighted average price of $9.06 per share. The following day, another 457,745 shares were purchased at an average of $9.55 each. The buying spree concluded on March 27th with the addition of 505,954 shares at a weighted average price of $9.79 per share.
These transactions have increased the holdings of the involved parties to a significant number of shares in ARS Pharmaceuticals, a company that operates within the pharmaceutical preparations industry. The purchases were made indirectly through various funds managed by RA Capital, including RA Capital Healthcare Fund LP and RA Capital Nexus Fund II, L.P.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.